The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

被引:4
|
作者
Li, Xiaoyan [1 ]
He, Jie [2 ,3 ]
Sun, Qiuhua [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Nursing, 548 Binwen Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Chengdu 610500, Sichuan, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Sichuan, Peoples R China
关键词
Sarcopenia; Metabolic dysfunction-associated steatotic; liver disease (MASLD); Prevalence; Systematic review; Meta-analysis; INSULIN-RESISTANCE; FIBROSIS; NAFLD; RISK; STEATOHEPATITIS; QUALITY;
D O I
10.1016/j.clnu.2024.07.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and aims: Sarcopenia is a common complication in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). However, the prevalence and its impact on the survival of sarcopenia in patients with MASLD is unknown. In this study, we aimed to assess the prevalence and effects of sarcopenia in patients with MASLD. Methods: Systematic review and meta-analysis of full texts of relevant studies were searched from inception until June 12, 2024 in five databases (PubMed, Cochrane Library, Embase, Web of Science, and the China National Knowledge Infrastructure). Next, we assessed the prevalence of sarcopenia in MASLD, and calculated the ORs and HRs between sarcopenia and MASLD based on the adjusted data from individual studies. Statistical analyses were performed using Stata 11.0. Results: Of the 2984 records considered, 29 studies recruiting 63,330 patients were included. The pooled prevalence of sarcopenia in patients with MASLD was 23.5% overall (95% CI; 19.1%-27.9%, I2 = 99.6%), and was higher in Asian patients, male, cross-sectional studies, when BIA were employed to measure muscle mass, one criterion of diagnosis sarcopenia, MASLD was diagnosed employing MRI, and moderate-quality studies. Sarcopenia was associated with MASLD patients (adjusted odds ratio [aOR] 2.08, 95% CI 1.58 -2.74, I2 = 93.6%) with similar findings in subgroups stratified by age, study design, methods for measuring muscle mass, assessment method to detect sarcopenia, and study quality. The association between all-cause mortality further supports the association between sarcopenia and poor prognosis with MASLD (aHR 1.59, 95% CI 1.33-1.91, I2 = 0%). Conclusions: Sarcopenia was strongly associated with MASLD progression and was a risk factor not only for MASLD pathogenesis but was also markedly correlated with MASLD-associated mortality. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2005 / 2016
页数:12
相关论文
共 50 条
  • [21] Prevalence of metabolic dysfunction-associated steatotic liver disease in people living with HIV and on antiretroviral treatment: A systematic review and meta-analysis protocol
    Sedibe, Amogelang
    Maswanganyi, Khanyisa
    Mzimela, Nomusa C.
    Gamede, Mlindeli
    HEALTH SCIENCE REPORTS, 2024, 7 (11)
  • [22] Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Singh, Avneet
    Buckholz, Adam
    Kumar, Sonal
    Newberry, Carolyn
    NUTRIENTS, 2024, 16 (05)
  • [23] Disparities for Hispanic Adults With Metabolic Dysfunction-associated Steatotic Liver Disease in the United States: A Systematic Review and Meta-analysis
    Tesfai, Kaleb
    Pace, Jordan
    El-Newihi, Nora
    Martinez, Maria Elena
    Tincopa, Monica A.
    Loomba, Rohit
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2025, 23 (02) : 236 - 249
  • [24] The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis
    Untaaveesup, Suvijak
    Kantagowit, Piyawat
    Ungprasert, Patompong
    Kitlertbanchong, Nitchanan
    Vajiraviroj, Tanyatorn
    Sutithavinkul, Tanpichcha
    Techataweewan, Gynna
    Eiumtrakul, Wongsathorn
    Threethrong, Rinrada
    Chaemsupaphan, Thanaboon
    Pratchyapruit, Walaiorn
    Sriphrapradang, Chutintorn
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
  • [25] Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis
    Mantovani, Alessandro
    Morandin, Riccardo
    Fiorio, Veronica
    Lando, Maria Giovanna
    Petta, Salvatore
    Ferraro, Pietro Manuel
    Targher, Giovanni
    INTERNAL AND EMERGENCY MEDICINE, 2024, 19 (06) : 1745 - 1755
  • [26] Association between phthalate exposure and metabolic dysfunction-associated steatotic liver disease (MASLD) - Systematic literature review
    Gogola, Tomasz
    Pitkanen, Sini
    Huovinen, Marjo
    Laitinen, Heikki
    Kublbeck, Jenni
    ENVIRONMENTAL RESEARCH, 2025, 273
  • [27] Association between metabolic dysfunction-associated steatotic liver disease and risk of thyroid cancer: a systematic review and meta-analysis
    Chen, Jiahao
    Gao, Yingzheng
    Fu, Tao
    Gu, Yi
    Du, Weidong
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 37 (02) : 119 - 128
  • [28] Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis
    Omana-Guzman, Isabel
    Rosas-Diaz, Marisol
    Martinez-Lopez, Yoscelina Estrella
    Perez-Navarro, L. Monserrat
    Diaz-Badillo, Alvaro
    Alanis, Anthony
    Bustamante, Alejandra
    Castillo-Ruiz, Octelina
    del Toro-Cisneros, Noemi
    Esquivel-Hernandez, Diego Armando
    Garcia-Villalobos, Gloria
    Garibay-Nieto, Nayely
    Garcia-Oropesa, Esperanza Milagros
    Hernandez-Martinez, Juan Carlos
    Lopez-Sosa, Elena Beatriz
    Maldonado, Carlos
    Martinez, David
    Membreno, Joshua
    Moctezuma-Chavez, Oscar Omar
    Munguia-Cisneros, Claudia X.
    Nava-Gonzalez, Edna J.
    Perales-Torres, Adriana L.
    Perez-Garcia, Adolfo
    Rivera-Marrero, Hector
    Valdez, Alisha
    Vazquez-Chavez, Alfonso Alejandro
    Ramirez-Pfeiffer, Carlos
    Carter, Kathleen V.
    Tapia, Beatriz
    Vela, Leonel
    Lopez-Alvarenga, Juan Carlos
    BMC MEDICINE, 2024, 22 (01):
  • [29] STATIN DECREASES THE RISK OF HEPATOCELLULAR CARCINOMA IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS. A SYSTEMATIC REVIEW AND META-ANALYSIS
    Tarar, Zahid Ijaz
    Farooq, Umer
    Basida, Sanket
    Gandhi, Mustafa
    Chaudhary, Ammad
    Kamal, Faisal
    Ali, Ahmad H.
    Ghouri, Yezaz A.
    GASTROENTEROLOGY, 2024, 166 (05) : S1651 - S1651
  • [30] Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Liu, Huan
    Yerevanian, Armen
    Westerhoff, Maria
    Hastings, Margaret H.
    Guerra, Justin Ralph Baldovino
    Zhao, Meng
    Svensson, Katrin J.
    Cai, Bishuang
    Soukas, Alexander A.
    Rosenzweig, Anthony
    DIABETES, 2024, 73 (02) : 260 - 279